Introduction
Medulloblastoma (MB) is a pediatric cancer affecting the cerebellum and representing the most frequent malignant brain tumor in children (1) . Four molecular subtypes have been classified and one of these subgroups (which accounts for approx. one third of cases) is driven by excessive Hedgehog (Hh) signaling (2) . In the developing cerebellum Purkinje cell-derived Sonic Hh (SHH, one of three mammalian Hh ligands) serves as a potent mitogen for granule cell precursors (GCPs), which transiently amplify and later constitute the internal granule cell layer (IGL) of the cerebellum. Persistent Hh signaling expands the number of GCPs in an uncontrolled manner, resulting in the formation of malignant medulloblastoma, a lethal condition if left untreated (3) . Current treatment schemes employing radiation, chemotherapy and surgery lead to appreciable survival rates but are often associated with life-long impairments due to unspecific damage of the developing brain (1) .
Mechanistically, the Hh ligands bind to Patched (PTCH1 or PTCH2) receptors situated in the membrane of a specialized organelle, the primary cilium, of receiving cells (4, 5) . The immotile primary cilium represents a sensory structure present on most cell types and is held in place by a microtubule (MT)-based axoneme (6) . Motor protein transport by IFT (Intraflagellar transport) complexes along the MT tracks regulates the assembly, function, and the disassembly of this organelle (7) . The tubulin subunits of the ciliary axoneme contain posttranslational modifications associated with long-lived MTs, such as the acetylation of α-tubulin. An important modulator of tubulin acetylation is histone deacetylase 6 (HDAC6), a mainly cytoplasmic member of the HDAC family which uses tubulin as one of its major substrates (8, 9) .
Binding of Hh ligands to PTCH1 allows for the entry of Smoothened (SMO) proteins into the cilium and the subsequent dissociation of SUFU (Suppressor of Fused, a cardinal negative regulator of Hh signaling) from GLI transcription factors (10) . Specifically, free GLI2 and GLI3 are activated in the cilium and can subsequently enter the nucleus to induce target gene transcription (11, 12) . The transcriptional targets include Hh pathway specific genes such as PTCH1 and GLI1 as well as more cell type specific genes such as N-Myc, BMI1 or D-type
Cyclins.
Recently, potent pharmacological inhibitors targeting SMO, the key upstream bottleneck in the Hh cascade, have been introduced to the clinic (13) . While very promising first results have underscored the principle effectiveness of targeting Hh signaling in MB, the rapid development of drug resistance has dampened the initial enthusiasm (14) (15) (16) . These data encourage for the development of additional inhibitors which could be applied together with SMO inhibitors or as single agent therapy in refractory situations. Since the major mechanisms of the development of drug resistance seems to involve SMO mutations affecting the drug binding site or the activation of SMO-bypassing downstream events (17), novel Hh pathway inhibitors would ideally target a non-SMO protein which is acting at a later step in the signaling cascade (18) .
We found HDAC6 to be overexpressed in a murine model of Hh-driven MB and were interested to see if this enzyme plays a role in the Hh pathway itself and in MB. Our results show that HDAC6 significantly regulates Hh signaling, playing a dichotomous role: On the one hand its enzymatic activity represses basal Hh target gene transcription while on the other hand HDAC6 activity promotes the maximum expression of target genes. Using an allograft model of Hh-elicited MB, we could show that despite this dichotomous effect of HDAC6 on the Hh pathway, specific inhibitors of this enzyme significantly reduced in vivo tumor growth.
In light of the fact that the genetic knock-out of Hdac6 does not show a prominent phenotype (19) , selective HDAC6 antagonists represent an interesting new class of potential drugs in the treatment of medulloblastoma.
Material and Methods

Reagents
Smoothened agonist SAG was purchased from Calbiochem. Trichostatin A (TSA) and SANT (SANT-1) were from Sigma. Tubacin was kindly provided by Ralph Mazitschek and Stuart Schreiber (Initiative for Chemical Genetics-NCI) and was also purchased from Enzo Life Sciences. CAY-10603 was purchased from Biomol. ACY-1215 for cell culture experiments was purchased from Selleck Bio and larger amounts for animal studies were bought from Xcess Bio. Lists of antibodies, siRNA sequences and qPCR primers used in this study can be found in tables S1, S2 and S3, respectively. Separation of lysates by SDS-PAGE was followed by subsequent Western Blot analysis.
Cell lines
SDS-PAGE gels were blotted on Immobilon-PVDF membranes (Millipore) and incubated with the respective primary antibody, followed by an HRP-coupled secondary antibody.
Detection of the HRP signal was performed using Pierce ECL Western Blotting Substrate (Thermo Scientific) according to the manufacturer's protocol.
Immunohistochemistry
Immunohistochemistry on formaldehyde-fixed and paraffin-embedded tissue sections was performed using an HDAC6 antibody (1:50) from Santa Cruz (sc-11420).
RNA preparation, cDNA synthesis, qPCR
Total RNA was extracted using NucleoSpin RNA II kit (Macherey-Nagel) according to the manufacturer's protocol. cDNA synthesis of 1 μg total RNA was performed using iScript cDNA Synthesis Kit (Biorad) following the manufacturer's guidelines. Quantitative PCR reactions were performed using the Absolute QPCR SYBR Green Mix (ABGene). qPCR reactions were performed on 96 well qPCR plates (ABGene) using either the Mx3000P or Mx3005P qPCR systems (Agilent). Results were calculated as relative mRNA expression (2 ΔΔCt ). Data was obtained from at least three independent experiments and is shown as the mean ± StDev.
Luciferase reporter assays
ShhL2 cells were plated in triplicate and were grown to full confluence in solid white 96well
plates with clear bottom. Subsequently, cells were treated in full growth medium with 100 nM SAG plus the indicated compounds for 48 h. Cells were lysed in Passive Lysis Buffer (Promega) and Firefly and Renilla Luciferase activity were measured using an Orion L microplate luminometer (Berthold Detection Systems) using Beetle-and Renilla-Juice reagents (both PJK).
Osteogenic differentiation assay
The mesenchymal progenitor cell line C3H10T1/2 was plated in triplicates and grown to full confluence in 96well plates. Subsequently, cells were exposed to experimental compounds in full growth medium for 4d. Afterwards, cells were lysed in Passive Lysis Buffer (Promega). A part of the lysate was used for protein quantification (Biorad Protein Assay, Biorad) while the remaining lysate was used for measuring alkaline phosphatase activity (Alkaline Phosphatase
Blue Microwell Substrate, Sigma).
Mouse lines
The Neurod2-SmoA1 mouse line was purchased from JAX (stock number 008831) and is described in (22) . peritumoral with an average distance to the tumor mass of approx. 0.5-1 cm. Mice were sacrificed on day 12 by cervical dislocation and tumors were removed for further analysis.
Animal studies
Solubilization of compounds: The compounds were first dissolved in 100% DMSO at a concentration of 70 mg/ml. Then, compounds were diluted in 45% (2-Hydroxypropyl)-β-Cyclodextrin (Sigma #332607) in PBS for a final concentration of 5 mg/ml (1mg/200µl). All animal studies were approved and were in agreement with institutional and federal state laws.
RNAi transfection and Microarray
Subconfluent MEF
[SHH] cells were transfected with 35 nM siRNA (Dharmacon SMARTpools) on day 0 using Lipofectamine RNAiMAX (Invitrogen) as transfection reagent. On day 1 (24 h post transfection), the cells were confluent and the siRNA solution was exchanged against full growth medium. Cells were grown for another 48 h and were harvested for RNA preparation on day 3 (72 h post transfection). The integrity of the isolated RNA was subsequently determined using the Experion Automated Electrophoresis System (Biorad). The RNAs from two independent experiments were pooled in a 1:1 ratio. Labeling, hybridization to microarrays and data analysis were performed by the IMT Genomics Core Facility. RNA was labelled with the two-color Quick-Amp Labelling kit (Agilent) and hybridized against Agilent-026655 microarrays. Raw microarray data were normalized using the 'loess' method implemented within the marray package of R/Bioconductor. Agilent probes were reassigned to the Ensembl revision 70 genome annotations by aligning sequences with a short read aligner (Bowtie against both, the transcriptome and the genome) as described in (23) . The microarray data have been deposited at Array Express under the accession number E-MTAB-2440. 
Statistical analysis
Results
Histone deacetylase 6 is overexpressed in murine medulloblastoma
Histone deacetylase 6 (HDAC6) had been implicated in the etiology of several cancers and in primary cilium biology (9, (24) (25) (26) (27) , which prompted us to analyze the role of HDAC6 in Hhdriven MB. In line with an earlier report (28) 
Pharmacological HDAC6 inhibitors block active Hh signaling
In order to address the relevance of HDAC6 in Hh-evoked disease, we were first interested to see whether this enzyme plays a role in the Hh pathway itself. To this end, we utilized three structurally distinct, specific HDAC6 antagonists (Tubacin, CAY-10603 and ACY-1215), which had been described and characterized before (26, 30, 31) (Figure 2A ). We treated fibroblasts with these inhibitors since they represent a good model system for the analysis of effects. In order to rule out negative effects of the compounds on ciliogenesis, we analyzed the presence of primary cilia in treated cells. In line with HDAC6 stabilizing rather than destabilizing cilia (9, 27), we found no significant reduction of ciliogenesis or change in cilia morphology in cells exposed to HDAC6 inhibitors, irrespective of the serum concentrations used ( Figure S1A ,B,C). Moreover, HDAC6-inhibition was not associated with gross cellular toxicity ( Figure S2A ).
In order to extend our investigations, we tested the impact of HDAC6 inhibition on a physiological Hh-driven process. Mesenchymal progenitor cells (C3H10T1/2 cells) differentiate along the osteogenic lineage upon treatment with Hh, a process which can be visualized by staining for alkaline phosphatase (AP) activity, an osteogenic marker protein.
As can be seen in figures 2C and 2D, the SAG-induced differentiation of C3H10T1/2 cells could be potently antagonized by application of the HDAC6 inhibitors CAY-10603 or Tubacin. Interestingly, the pan-HDAC inhibitor Trichostatin A (TSA) also blocked SMOinduced cell differentiation, but in addition also resulted in an increase of basal induction ( Figure 2D ). This suggests that nuclear HDAC family members repress basal Hh signaling and further underlines the specificity of the HDAC6 inhibitors used in this study. However, in order to demonstrate the requirement for HDAC6 in Hh signaling with a chemical compoundindependent approach, we used a pool of four different RNAi constructs to selectively knockdown endogenous Hdac6 mRNA in mouse embryonic fibroblasts stably transfected with Sonic Hedgehog (MEF [SHH] ; (21) S3B ). Taken together, our data show that HDAC6 functions in the Hh pathway and is required to achieve full pathway activity.
Epistatic analysis of HDAC6 effects
Next, we were interested to learn at which point in the Hh transduction cascade the HDAC6 functions would be integrated. To this end, we made use of MEF cell lines which harbor activating alterations to stimulate Hh signaling at different levels of the pathway and measured the abundance of the Hh target genes Gli1, Ptch1, Ptch2 and Hip1. As can be seen in figure 3A and 3B, signaling in MEF [SHH] Figure 3D ). Additional evidence for pathway inhibition in Sufu-/-cells was also found upon RNAi-mediated knockdown of Hdac6 ( Figure S3D ).
Finally, we utilized cells with stable expression of low levels of an activated mutant of GLI2, the transcription factor mediating the final steps of the Hh signaling cascade (MEF [Gli2dN] cells; (21)). As can be seen in figure 3E , HDAC6 blockade also repressed Hh target gene expression in these cells, whereas the upstream inhibitor SANT was inactive. Again, the inhibition achieved by HDAC6 blockade was not as pronounced as in cells with Hh pathway activation at the ligand step (e.g. MEF [SHH] ). Since direct deacetylation by nuclear HDACs had been shown to stimulate GLI function (34), we were interested if a similar mechanism applied to HDAC6 as well. Whereas HDAC1 and HDAC2 significantly promoted the activity of transfected GLI1 in luciferase reporter assays, HDAC6 remained inactive, despite prominent protein expression ( Figure 3F ). This result demonstrates that HDAC6 does apparently not act through direct deacetylation of the GLI1 transcription factor and that it most likely functions through indirect mechanisms (which were overwhelmed by the high levels of transfected GLI1 in this assay). 
In summary, we conclude that HDAC6 positively regulates Hh signaling, potentially at two levels: First at the receptor level (PTCH1/SMO) and second at a downstream point in the cascade at the level of the transcription factors.
Global analysis of HDAC6 inhibition
After having observed the antagonistic effects of HDAC6 inhibition in specific Hh assays, we were interested to investigate the wider impact on the Hh-induced transcriptome. To this end, we treated MEF [SHH] cells with control siRNA (targeting firefly luciferase, siLuc) or RNAi against Hdac6. As reference constructs, we used siRNA targeting Smo, Gli1 or Gli2. RNA from these cells was subjected to microarray analysis. Confirming previous data, established
Hh target genes such as Ptch2 or Hip1 (Hhip) were downregulated in all sample groups compared to the control siRNA (not shown).
In order to compare global expression differences between siSmo and siHdac6 transfected samples, we employed a scatter plot to represent the data. Based on the observed gene expression changes we classified the transcripts into 8 different categories, which can be seen as color-coded spots in the scatter plot in figure 4A . In order to investigate how these genes behave in a subsequent comparison to siGli1 and siGli2 conditions, we transferred these transcripts (and their color) into siGli1-and siGli2 scatter plots ( Figure 4A , middle and right panel).
Comparison of the expression changes induced upon siSmo and siHdac6 transfection revealed that, as expected, the well-established canonical Hh target genes (e.g. Ptch1, Ptch2) fall into group 6 ( Figure 4A , left panel, purple spots) and were downregulated by both siRNAs. Not unexpectedly, these genes were also regulated in the same direction by siGli1 and siGli2
(purple and pink spots in figure 4A , middle and right panel). Interestingly, genes which were regulated in opposite directions by siSmo and siHdac6 (groups 1 and 8, orange and brown colored spots) were basically absent. 
Another interesting set of genes fell into class 7 and was downregulated upon siHdac6, but was not affected by siSmo. However, a substantial fraction of these genes (red colored spots in figure 4A ) was shifted to the left in siGli1 and siGli2 plots, indicating that they were regulated by Gli transcription factors and by Hdac6, but not by Smo. Finally, sets of genes exist which were regulated by Smo, but not by Hdac6 (groups 4 and 5 (green and grey spots) in figure 4A ). Intriguingly, a large fraction of these genes was not regulated by Gli1 or Gli2 either.
Given the fact that not all Smo-regulated genes were also affected by Gli1/2 (and vice versa), we defined a common set of genes termed the 'Hh signature'. This gene set fulfilled the following stringent criteria: Genes must have been (i) regulated in siSmo samples compared to siControl and (ii) in addition, siSmo-regulated genes had to be regulated in the same direction by either siGli1 or siGli2 transfection. This resulted in a set of genes encompassing 820 transcripts (the 'Hh signature'). Comparing the Hh signature with genes regulated upon knockdown of Hdac6 revealed that 56 % of the Hh signature were affected by loss of Hdac6 ( Figure 4B ).
The expression data were validated by qPCR analysis of selected genes predicted to be regulated by 'Gli1 and Hdac6' and by 'Gli1 only'. As can be seen in figure 4C , canonical Hh targets such as Hip1, Ptch1 and Ptch2 were all downregulated by siGli1 as well as by siHdac6 transfection in MEF [SHH] cells. In contrast, the expression of Hsd11b1, Rasl11b and Foxj1 were selectively affected by Gli1, but not by Hdac6, demonstrating that HDAC6 affects a subset of Gli target genes, as predicted by the microarray experiment.
In conclusion, HDAC6 activity affected more than half of the genes included in the Hh signature, but it did not affect all genes in the Hh signature. Interestingly, HDAC6 impinged also on the regulation of genes, which are Smo-independent yet Gli-dependent, arguing for some degree of downstream pathway control by HDAC6. 
Dichotomous impact of HDAC6 on Hh signaling
In order to learn more about the underlying molecular links between HDAC6 and Hh, we turned to GLI2 and GLI3, the principle downstream signal transducers in the cascade.
Because HDAC6 had been implicated in protein degradation and clearance (35-41), we asked whether HDAC6 inhibition would affect the protein levels or the processing of GLI2/3. functional Gli2 and Gli3 genes (double knockout Gli23-/-MEFs; (21) ). Treating these cells with pharmacological HDAC6 inhibitors revealed that the Gli1 induction seen in wildtype cells was significantly reduced in the absence of Gli2 and Gli3 (Figure 5E ), suggesting that in particular the HDAC6-mediated effects on the GLI3 R protein levels might be important.
However, positive effects through Gli1 might be needed for the ligand-independent Hh target gene induction as well. Therefore, we reduced endogenous Gli1 levels by RNAi-mediated knockdown of the remaining Gli1 expression in Gli23-/-cells. As shown in figure 5F , siGli1
transfection reduced the Hh target gene induction (Ptch1, Ptch2) compared to siControl cells, arguing also for the requirement of GLI1 activator function ( Figure 5F ).
Taken together, we found a dichotomous behavior of HDAC6 inhibitors on Hh signaling: On the one hand, HDAC6 blockade results in a suppression of maximal Hh target gene expression; while on the other hand HDAC6 interference stimulates basal target gene transcription. We hypothesize that the first observation might be caused by the reduced Gli2 mRNA expression upon HDAC6 inhibitor exposure, whereas the latter effect most likely involves the reduced GLI3 R protein in combination with GLI1 activator functions.
Pharmacological HDAC6 inhibition has suppressive effects on in vivo MB growth
Next, we were interested to investigate whether an HDAC6-directed approach could in principle be exploited as a future therapy option in the treatment of MB. To address this issue, we exposed primary mouse MB cells (MB99-1 cells derived from the SmoA1 mouse model; (22, 29) ) to increasing concentrations of HDAC6 inhibitors in culture and measured surviving cells by cell titer assays ( Figure 6A ,B,C). As can be seen in figure 6A , This was also reflected in the mean tumor weight of dissected tumors taken at the end of the experiment ( Figure 6E ). Notably, all drugs were well tolerated by the animals with no obvious signs of toxicity.
Immunohistological examination of the tumor tissue revealed that in particular ACY-1215-treated tumors had high levels of cleaved caspase 3, a marker of apoptotic cell death ( Figure   6F ), despite the fact that both drugs (Vismodegib and ACY-1215) suppressed Hh pathway activity in the in vivo allografts, as measured by reduced Hh target gene expression ( Figure   S5 ). 
Discussion
Histone deacetylase 6 belongs to the family of histone deacetylases but mainly acts on nonhistone substrates. The enzyme can be found in the cytoplasm as well as in the nucleus of cells, depending on the differentiation status (42) . In the cytosol, many substrates and interacting proteins have been described, including cortactin, Hsp90 and peroxiredoxins (43) (44) (45) (46) (47) (48) (49) . One of the most prominent and best characterized protein substrate is the α-subunit of tubulin (8, 50) , through which the enzyme regulates microtubule dynamics and vesicular transport (51) (52) (53) . In addition, cytoplasmic functions of HDAC6 also include the formation of higher-order multiprotein complexes such as the protein-degrading aggresome as well as RNA/protein-containing stress granules (54, 55) . In addition, HDAC6 is involved in the regulation of autophagy and several signal transduction cascades (39, 41, (56) (57) (58) (59) . Moreover, HDAC6 plays a role in the nucleus as a modifier of gene transcription (42, (60) (61) (62) . Given the plethora of actions in which HDAC6 is involved it is more than surprising to note that Hdac6 null animals are viable and healthy and have only a very gentle phenotype (19) . It is currently not clear if the observed defects in immune response and the increased bone mineral density in these animals are linked to abnormal changes in Hh signaling but it should be mentioned that this pathway plays a role in these processes.
In our study we found HDAC6 to be overexpressed in Hh-induced MB and we wondered whether this enzyme plays a functional role in the signal transduction of this pathway. In fact, HDAC6 overexpression has been observed in MB before (28) , but no link to the Hh system was made. Surprisingly, these authors saw no effect of the HDAC6 inhibitor Tubastatin on granule cell proliferation or allograft growth (28) , which might be related to the relatively low concentrations used. In our hands, prominent Hh inhibition required the use of higher concentrations of HDAC6 inhibitors, indicative of the need to fully block HDAC6 in order to 
impact on the Hedgehog system. Despite the use of higher inhibitor concentrations, the compounds selectively inhibited HDAC6 and displayed no prominent effect on histone acetylation levels. We should point out that an allograft system always suffers from its artificial nature and that direct compound injections can potentially lead to high local inhibitor concentrations, although we tried to circumvent this issue by changing the injection sites and by not injecting directly into the tumor. It is worth noting that newer HDAC6 inhibitors are able to penetrate the blood-brain barrier and can therefore be tested under more physiological conditions in autochthonous MB mouse models in the future (63) . Interestingly, these newer was not observed in the differentiation assays using C3H10T1/2 cells or in reporter assays with ShhL2 cells, suggesting either cell-type differences or that the HDAC6-induced derepression of Hh target genes is not sufficiently strong enough for certain biological processes to occur. However, it is noteworthy that in our in vivo allograft model, mice receiving the SMO antagonist Vismodegib presented with hair loss at the cutaneous injection sites ( Figure   S6 ). This is not unexpected as Hh signaling is well known to promote hair growth. The alopecia seen in VIS-treated mice was not observed in the ACY-1215 animal cohort, despite the fact that the Hh pathway was blocked. Our microarray analysis revealed that approx. half of the SMO/GLI-regulated genes are affected by HDAC6 and one hypothetical reason for the lack of alopecia might be that HDAC6 does not affect the Hh target genes required in hair cell biology. This observation warrants further investigation as it could be used to circumvent unwanted side effects associated with blocking Hh-dependent physiological processes. In addition, an unexplored question as of now is whether HDAC6 inhibition affects SMOdependent, but GLI-independent non-canonical signaling (65, 66) .
We hypothesize that the impact of HDAC6 on Hh signaling could be linked to its effect on tubulin acetylation and is not mediated by direct deacetylation of GLI proteins through HDAC6. Posttranslational modifications of tubulin have been shown to affect motor proteindriven transport along MT. As Hh signaling critically requires IFT transport towards and from primary cilia (67) (68) (69) , interfering with these transport processes might in turn suppress the precisely coordinated Hh signal transduction. As such, prolonged increased tubulin acetylation might functionally (not morphologically) resemble cilia defects such as those typically induced by loss-of-function of IFT components. In fact, certain HDAC6-related aspects of our data presented here, such as the reduced GLI3 R levels and the ligandindependent pathway activation, are in agreement with previous reports on cilia defects (70) (71) (72) (73) (74) . The fact that HDAC6 inhibition negatively affects the Hh pathway in Sufu-/-cells, which signal cilium-independently (75, 76) , suggests that other intracellular transport processes might be required downstream of SMO and primary cilia.
An alternative scenario would involve the nuclear HDAC6 fraction which might impinge on transcriptional complexes governing Hh target gene expression, such as Gli2 transcription.
Importantly, we could demonstrate the HDAC6-specificity of our reagents in several instances and thus exclude the role of histone-directed nuclear members of the HDAC family, which also modulate Hh signaling (34) .
Interestingly, recent work implicates cilia-like processes at the immunological synapse (77), a cellular structure which had previously been linked to HDAC6 (78 HDAC6 has been shown to possess oncogenic traits in several tumors (25, 79, 80) . In light of these findings and the requirement for HDAC6 to achieve maximal Hh signaling, we evaluated the impact of an HDAC6-directed therapy in an in vivo allograft model of MB. 
